Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Anetumab ravtansine (Primary) ; Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2018 Status changed from not yet recruiting to recruiting.
- 12 Jun 2018 Planned initiation date changed from 23 May 2018 to 23 Aug 2018.